The validation comes from outside.
We don't ask you to take our word for it. The value of the field is documented by third parties: the capital flowing into it, the demand it expresses, the science that supports it. What follows is not about Longevilife's results, but about the context in which Longevilife operates.
A structurally growing market.
Estimates and projections are third-party, cited with source and date. They remain projections, not forecasts of results.
- —Global anti-aging and longevity market.According to Grand View Research, estimated at around USD 100 billion in 2025 and projected toward roughly USD 400 billion by 2033, with a compound annual growth rate estimated at about 18%. (Source: Grand View Research, 2025 data.)
- —Private healthcare spending in Italy.According to data cited by Italy's State General Accounting Office (Ragioneria Generale dello Stato), private healthcare spending exceeds EUR 40 billion, growing year on year, amid a progressive defunding of public healthcare. (Source: Ragioneria Generale dello Stato; elaboration on 2024 data.)
Where the capital goes.
Rounds as reported by sector press, cited with source and date. These are third-party deals: they validate the field, not Longevilife's services.
- —Neko Health — Series B.As reported by sector press, it raised a round of around USD 260 million at a valuation of about USD 1.8 billion. (Source: company communications and sector press, January 2025.)
- —Function Health — Series B.As reported, it raised a round of around USD 298 million at a valuation of USD 2.5 billion. (Source: sector press, November 2025.)
International venture capital is funding measurable-longevity and scalable-prevention models. It is a signal about the field, not a forecast of Longevilife's results.
A solid scientific base.
Peer-reviewed evidence on the field. Each indicator is documented or associated with health outcomes, never presented as a promise of results.
- —Grip strength and mortality.The association is documented on very large cohorts. (Source: UK Biobank, BMJ 2018, n ≈ 500,000.)
- —Glycated hemoglobin (HbA1c).Associated with mortality and cardiovascular events. (Source: EPIC-Norfolk, Annals of Internal Medicine, 2004.)
- —VO₂max.Among the strongest predictors of survival in the literature. (Source: Mandsager et al., JAMA Network Open, 2018.)
- —Epigenetic clocks.Indicators such as GrimAge and DunedinPACE are the subject of consolidated research on biological aging. (Source: Duke/Columbia research groups; Horvath.)
Why Longevilife, and why now.
Capital, demand and science validate the field globally. In Italy a clinically serious, continuous, data-driven longevity medicine ecosystem does not exist yet; in Europe it exists but is fragmented. Longevilife brings a disciplined, replicable, capital-light model to a market that is ready.
Capital-light Hub: the model plugs into already-authorized clinics, instead of building new ones.
Italian first mover: we are first to bring to Italy a data-driven model built on data and continuity of care.
Anti-hype discipline: we communicate only what research documents, and we state our limits.
The data reported on this page comes from third-party sources and refers to the market, capital and scientific research of the longevity sector. It validates the field in which we operate, not Longevilife's services. Sources are indicated next to each figure; market estimates are third-party projections and do not constitute forecasts of Longevilife's results.
The context is convincing. The model is in the dossier.
The thesis, model and project scope are in a dossier we share on qualified request.